Exopharm Limited (EX1.AX)

0.0110 0.0000 (0.00%) At close: 10:10AM AEST

Exopharm Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 8419 0827
https://exopharm.com

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.	Founder, Technology Co-Founder, CEO MD & Director	361.79k	N/A	N/A
Dr. Gregor Lichtfuss M.Sc.	Co-Founder & Business Services Manager	228.54k	N/A	N/A
Mr. Johannes Muhl	Senior Vice President of Finance	N/A	N/A	N/A
Mr. David James Franks BEc, C.A., F Fin, J.P.	Company Secretary	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine. The company was incorporated in 2013 and is based in Camberwell, Australia.

Corporate governance

Exopharm Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.